TACE combined with regorafenib with or without anti-PD-1 therapy for advanced HCC after targeted therapy failure: a multicenter real-world study.

Similarly, when assessed by RECIST v1.1, the TRP group maintained a higher DCR (60.9% vs 40.6%, P = 0.018) and a numerically increased ORR (23.4% vs 10.9%, P = 0.061), though the latter did not reach statistical significance.

also in 111,027 other papers